Biocompatibles CE-marks embolisation beads:
This article was originally published in Clinica
Executive Summary
Biocompatibles International has CE-marked for sale in Europe its Bead Block embolisation therapy for preventing blood flow to a tumour. The microspheres-based product can provide a minimally invasive alternative to hysterectomy in the treatment of uterine fibroids, says the UK firm. It may also provide a platform for targeted drug delivery. The Farnham, Surrey company has initiated a programme for drug-eluting embolics based on the product which will initially target malignant tumours, such as liver cancer. Bead Block is to be distributed exclusively by Terumo in Europe, Israel and North Africa. It is already approved in the US, where Biocompatibles is seeking approval for the uterine fibroid indication.